Synopsis

Source of validity: Scientific
Rating (out of 5): 2

AMP-activated protein kinase (AMPK) is an important cellular energy sensor and regulator of metabolic homeostasis. Its activation has been studied in the context of Chronic Obstructive Pulmonary Disease (COPD), primarily in preclinical models. Scientific interest in AMPK as a therapeutic target for COPD is based on its roles in reducing inflammation, oxidative stress, and cellular senescence—all of which contribute to COPD pathogenesis. Several animal and cell culture studies have shown that pharmacological activation of AMPK (using agents such as metformin, AICAR, or natural compounds like resveratrol) can attenuate inflammatory responses, reduce airway remodeling, and decrease emphysema-like changes in models of cigarette smoke-induced lung injury.

Specifically, AMPK activation inhibits nuclear factor-kappa B (NF-κB) signaling, which is a key driver of inflammation in COPD. It also enhances autophagy, a process that helps clear damaged cellular components, and preserves mitochondrial function, potentially protecting airway cells from damage. Some retrospective clinical studies have suggested that patients with COPD taking metformin (an AMPK activator) have better outcomes, but these findings are not yet conclusive, and no large-scale randomized clinical trials have established AMPK activators as standard COPD therapy.

In summary, there is a scientific rationale and promising preclinical evidence for targeting AMPK in COPD, but direct clinical evidence is limited. Thus, the evidence supporting AMPK use in COPD is rated as 2/5, reflecting early-stage research with insufficient validation for routine clinical use.

More about AMP-activated protein kinase (AMPK)
More about Chronic Obstructive Pulmonary Disorder

Other ingredients used for Chronic Obstructive Pulmonary Disorder

Other health conditions supported by AMP-activated protein kinase (AMPK)

Products containing AMP-activated protein kinase (AMPK)